Women Rising Panel Discussion
Sarah Lively
Senior Director, External Innovation, Johnson & Johnson
The Pharmaceuticals business of the Johnson & Johnson Family of Companies is focused in five core therapeutic areas, Cardiovascular, Metabolism, Retina & Pulmonary Hypertension; Immunology; Infectious Diseases & Vaccines; Neuroscience; and Oncology. In addition, we have teams dedicated to Diagnostics & Enabling Technologies; Global Public Health; Emerging Markets; and Divestitures & Out-licensing. Janssen Business Development seeks opportunities across all of these areas where there is strong science and significant unmet patient need. We are also pioneering Data Science and digital healthcare and reimagining how we research, develop and deliver transformational medicines to patients around the world.
Sarah Lively, Senior Director, External Innovation, Discovery, Product Development & Supply (DPDS), is located at the Johnson & Johnson Innovation Center in South San Francisco, California. In this role, she has overall strategic and operational responsibility for the scouting and evaluation of external opportunities for DPDS in Western North America, Australia and New Zealand across all synthetic drug modalities. She provides transactional support from a scientific and strategic perspective for DPDS-driven deals and assists the Therapeutic Area Innovation Leads with her scientific and technological expertise. Sarah also partners with the JLABS organization to identify and foster start-up companies that are aligned with DPDS strategy. Sarah has more than 20 years of experience in the biotech and pharmaceutical industries and has taken the lead in various small molecule discovery programs across a range of therapeutic areas, most notably at Tularik and Amgen.